Share this Article
Aung TH, Go YY, Low LP, Chua T
Correspondence: A/Prof Terrance Siang Jin Chua, email@example.com
Introduction Hyperlipidaemia is a major risk factor for coronary artery disease (CAD). Its effective treatment has been shown to reduce the incidence of cardiovascular events, both in secondary and primary prevention. An essential component of risk factor management at the community level is public awareness and knowledge of treatment benefits. However, this data is limited in Singapore.
Methods A cross-sectional survey questionnaire of public perception and knowledge on cholesterol treatment among adult Singaporeans aged 30–69 years was commissioned by the Singapore Heart Foundation and conducted by a professional market survey company. Regional quota sampling was performed to ensure that the sample was representative of the Singapore population. This was followed by random sampling of households and respondents.
Results Of the 365 respondents, 40.9% were male, 70.3% were Chinese, 18.8% Malay and 10.9% Indian. The mean age was 47.5 years. Although 81.9% of respondents had medical check-ups involving blood tests, only 11.0% knew their actual cholesterol levels. A third of the respondents saw herbal medicine as healthier and safer than Western medication. More than 80% of respondents believed that diet and exercise were equally effective at lowering cholesterol as medication. About half of the respondents associated long-term use of statins with damage to the liver and kidney, while a third associated chronic statin use with the development of cancer.
Conclusion There are gaps in the level of public awareness and understanding of cholesterol treatment in Singapore. Common misconceptions should be addressed, as they could potentially impair effective management or treatment compliance.
Singapore Med J 2013; 54:32-35; http://dx.doi.org/10.11622/smedj.2013008
|1. Ministry of Health, Singapore. Singapore Health Facts 2010. Singapore, 2010.|
|2. Ministry of Health, Singapore. Disease Burden. In: Singapore Health Facts [online]. Available at: www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Di.... Accessed August 15, 2012.|
|3. Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA 1998; 280:2099-104.
|4. Ford I, Murray H, Packard CJ, et al. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-86.
|5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
|6. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 highrisk individuals: a randomised controlled trial. Lancet 2011; 378:2013-20. http://dx.doi.org/10.1016/S0140-6736(11)61125-2|
|7. Nash IS, Mosca L, Blumenthal RS, et al. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med 2003; 163:1597-600.
|8. Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006; 4:205-12.
|9. Yoon SS, Carroll MD, Johnson CL, Gu Q. Cholesterol management in the United States: the national health and nutrition examination survey, 1999 to 2006. Ann Epidemiol 2011; 21:318-26.
|10. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
|11. Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol 2006; 97:95C-97C.
|12. Kandula NR, Tirodkar MA, Lauderdale DS, et al. Knowledge gaps and misconceptions about coronary heart disease among US South Asians. Am J Prev Med 2010; 38:439-42.